Your browser doesn't support javascript.
loading
Patterns of relapse for children with localized intracranial ependymoma.
De, Brian; Khakoo, Yasmin; Souweidane, Mark M; Dunkel, Ira J; Patel, Suchit H; Gilheeney, Stephen W; De Braganca, Kevin C; Karajannis, Matthias A; Wolden, Suzanne L.
Afiliação
  • De B; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
  • Khakoo Y; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Souweidane MM; Department of Pediatrics, Weill Cornell Medical College, New York, NY, USA.
  • Dunkel IJ; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Patel SH; Department of Pediatrics, Weill Cornell Medical College, New York, NY, USA.
  • Gilheeney SW; Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • De Braganca KC; Department of Neurological Surgery, Weill Cornell Medical College, New York, NY, USA.
  • Karajannis MA; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Wolden SL; Department of Pediatrics, Weill Cornell Medical College, New York, NY, USA.
J Neurooncol ; 138(2): 435-445, 2018 Jun.
Article em En | MEDLINE | ID: mdl-29511977
ABSTRACT
We examined patterns of relapse and prognostic factors in children with intracranial ependymoma. Records of 82 children diagnosed with localized intracranial ependymoma were reviewed. 52% first presented to our institution after relapse. Median age at initial diagnosis was 4 years (range 0-18 years). Gender was 55% male. Initial tumor location was infratentorial in 71% and supratentorial in 29%. Histology was WHO Grade II in 32% and Grade III in 68%. As part of definitive management, 99% had surgery, 70% received RT (26% 2D/3D-conformal RT[CRT], 22% intensity-modulated RT [IMRT], 22% proton), and 37% received chemotherapy. Median follow-up was 4.6 years (range 0.2-32.9). Overall, 74% of patients relapsed (50% local, 17% distant, 7% local + distant) at a median 1.5 (range 0.1-17.5) years. Five-year OS and FFS for patients presenting prior to relapse are 70% (95% confidence interval [CI], 50-83%) and 48% (95% CI 30-64%), respectively. On log-rank, superior overall survival (OS) was demonstrated for gross total resection (p = 0.03). Superior failure-free survival (FFS) was demonstrated for age < 5 years (p = 0.04). No difference in OS or FFS was found between 2D/3D-CRT versus IMRT/proton (p > 0.05). On multivariate analysis, age ≤ 5 was independently associated with a lower risk of death and failure versus older patients (p < 0.05). Contrary to previous reports, young age may not be a poor prognostic factor in patients who can tolerate intensive treatment. Future studies examining patients stratified by clinical and molecular attributes are warranted.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Ependimoma Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Newborn Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Ependimoma Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Newborn Idioma: En Ano de publicação: 2018 Tipo de documento: Article